Samsung Biologics valuation
Valuation
The P/E ratio is 31.2. The average price target of 27 analysts is ₩1,879,148.10.
Data as of November 17, 2026
Samsung Biologics compared with similar companies
Samsung Biologics's P/E (trailing 12 months): 31.2, −21% against the median of a group of 8 similar companies (39.6).
| Metric | Samsung Biologics | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 31.2 | 39.6 | 34.1 – 62.3 | Low |
| Forward P/E | 30.5 | 30.5 | 24.1 – 40.5 | Middle |
| EV/EBITDA | 22.8 | 26.7 | 21.6 – 64.1 | Middle |
| Price/book | 7.80 | 4.53 | 3.05 – 9.11 | Middle |
| Price/sales | 12.9 | 9.97 | 7.06 – 30.5 | Middle |
| Gross margin | 54.2% | 61.9% | 51.6% – 76.9% | Middle |
| Operating margin | 45.5% | 26.8% | 14.4% – 32.0% | High |
| Net margin | 38.7% | 11.1% | 7.2% – 26.8% | High |
| ROE | 18.5% | 10.4% | 5.0% – 16.3% | High |
| Debt/equity | 0.15 | 0.15 | 0.07 – 0.38 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Samsung Biologics: valuation over time
On the latest fiscal year's earnings (2025), Samsung Biologics's P/E today is 37.3, below the median of its last 8 fiscal years (92.4; between 45.8 and 224.4 from 2018 to 2025). Relative to earnings, the stock costs less than it used to.
| Fiscal year | Price at year end | Earnings per share | P/E |
|---|---|---|---|
| 2025 | ₩1,695,000.00 | ₩37,040.39 | 45.8 |
| 2024 | ₩1,459,121.63 | ₩22,473.11 | 64.9 |
| 2023 | ₩1,168,527.38 | ₩18,528.27 | 63.1 |
| 2022 | ₩1,262,317.00 | ₩17,577.11 | 71.8 |
| 2021 | ₩1,373,812.00 | ₩9,146.19 | 150.2 |
| 2020 | ₩1,256,665.13 | ₩5,599.75 | 224.4 |
| 2019 | ₩658,760.31 | ₩4,715.07 | 139.7 |
| 2018 | ₩588,015.88 | ₩5,207.83 | 112.9 |
| 2017 | ₩564,434.38 | -₩2,253.43 | — |
| 2016 | ₩229,729.34 | -₩4,789.48 | — |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only). Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- ₩65.83T
- Enterprise value
- ₩64.41T
- PEG
- 1.56
- EV/revenue
- 12.6
Profitability and growth
- ROA
- 9.6%
- ROIC
- 23.6%
- Revenue growth (year over year)
- 30.2%
- Earnings growth (year over year)
- 32.9%
Financial health
- Total cash
- ₩2.21T
- Total debt
- ₩1.24T
- Current ratio
- 1.80
- Quick ratio
- 0.95
- Altman Z-Score
- 12.5
- Piotroski F-Score
- 8.00
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- ₩1,879,148.10
- Median price target
- ₩1,900,000.00
- High price target
- ₩2,200,000.00
- Low price target
- ₩1,350,000.00
- Analysts with a price target
- 27
- Consensus
- Buy
- EPS estimate, current year
- ₩38,761.64
Shares and trading
- Beta
- 0.15
- Average volume
- 60.27K
- Shares outstanding
- 46.55M
- Float
- 11.8M
- Institutional ownership
- 16.3%
- Insider ownership
- 74.4%
